Delving into the Latest Updates on Interferon Gamma(Materia Medica Holding Research And Production Company) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

Anaferon

Target

IFNGR

Mechanism

IFNGR stimulants(Interferon gamma receptor stimulants), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Bacterial InfectionsVirus Diseases

Inactive Indication-

Originator Organization

Materia Medica Holding Research And Production Company

Active Organization

Materia Medica Holding Research And Production Company

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 38623

Source: *****

Natural circulating antibodies (NAbs) to endogenous regulators have shown to be potential biomarkers in medicine. Due to the lack of reliable assays, only few of them have been well studied. To employ NAbs as biomarkers, an evaluation of changes over the course of a treatment is required. This paper describes our work to analyze the dynamics of NAbs titer to interferon-gamma (IFN-γ) among healthy children of different age and in patients with varicella infection receiving an antiviral drug Anaferon for children (AC, the API are highly diluted antibodies to IFN-γ) in comparison with placebo, and to correlate the findings with the treatment results. IFN-γ plays an essential role during varicella infection, and this fact causes the consequent increase of NAbs to IFN-γ level. The mean anti-IFN-γ NAbs level in the healthy volunteer group was 101 × 10³ U/ml (age: 0-15 years), which was significantly lower than the mean pre-treatment value in patients with varicella infection 167 × 10³ U/ml (age: 3-17 years). In the AC group, the NAbs level observed on days 5 and 10 decreased significantly to a level of 154 × 10³ U/ml, whereas in the placebo group it continued to rise in a time-dependent manner reaching 229 × 10³ U/ml on day 10. Our findings suggest that treatment with AC is characterized by "normalization" of the anti-IFN-γ NAbs levels in patients with varicella infection.

01 Jun 2017·Antiviral ResearchQ2 · MEDICINE

RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results

Q2 · MEDICINE

Article

Author: Tarasov, Sergey A ; Emelyanova, Alexandra G ; Gogsadze, Leila ; Khaitov, Musa R ; Walton, Ross P ; Gorbunov, Evgeniy A ; Petrova, Nataliia V ; Aniscenko, Julia ; Edwards, Michael R ; Epstein, Oleg I ; Bakhsoliani, Eteri ; Johnston, Sebastian L ; Bartlett, Nathan W

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.

01 May 2017·Journal of Medical VirologyQ4 · MEDICINE

Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model

Q4 · MEDICINE

Article

Author: Epstein, Оleg I. ; Morozov, Sergey G. ; Don, Еlena S. ; Petrova, Nataliia V. ; Gorbunov, Evgeniy A. ; Emelyanova, Alexandra G. ; Nikiforova, Marina V. ; Yakovleva, Natalia N. ; Tarasov, Sergey А.

The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-active form of antibodies to interferon-gamma) was tested in a dose-dependent manner (at doses of 0.13, 0.2, 0.4, 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2 lgEID50/20 mg of tissue; infected animals' life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose-response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released-active forms of antibodies. J. Med. Virol. 89:759-766, 2017. © 2016 Wiley Periodicals, Inc.

100 Deals associated with Interferon Gamma(Materia Medica Holding Research And Production Company)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB03	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	RU	Materia Medica Holding Research And Production Company	-
Virus Diseases	RU	Materia Medica Holding Research And Production Company	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03707912 (CTgov)	Phase 4	Acute respiratory infections	204	Anaferon (Anaferon)	sbqzivtksa(frdpfcnmba) = glbbxwzeoi thcgrcunis (heodreepjj, udszdvovax - zsurydhvja) View more	-	02 Sep 2020
				Placebo (Placebo)	sbqzivtksa(frdpfcnmba) = bhmquxrlrs thcgrcunis (heodreepjj, usuigiwolw - hspdzbuwqe) View more
NCT03301155 (CTgov)	Phase 4	Acute respiratory infections \| Influenza, Human	1,036	Anaferon for children (Anaferon for Children)	nzjdrvvgmg(joqyyvuqfs) = fjohiufkth zjxyppoimj (vicohovsre, hzcxluwjxj - wxfkepkjxg) View more	-	06 May 2020
				Placebo (Placebo)	nzjdrvvgmg(joqyyvuqfs) = yvlyxfepey zjxyppoimj (vicohovsre, ifejxzkmzb - gseygqgiwy) View more
NCT03162458 (CTgov)	Phase 3	Acute upper respiratory infection	142	Anaferon for children (liquid dosage form) (Anaferon for Children)	hvshxrjrwv(efynztdovm) = trxuxdfdip xmxnlyyjkd (iovrghqdkz, iokasebluk - mqozgfkbhf) View more	-	03 Aug 2018
				Placebo (liquid dosage form) (Placebo)	hvshxrjrwv(efynztdovm) = fnxmlapybl xmxnlyyjkd (iovrghqdkz, vukhuswhkc - mcuqkevejb) View more
NCT02072174 (CTgov)	Phase 4	Viral respiratory infection \| Acute respiratory infections \| Influenza, Human	569	Anaferon for Children (Anaferon for Children)	objkmfexbd(pxqttuazwu) = fjvbwjzale uzeauhdfhs (zwjkwacwoc, laxbfoisoj - ngkcvnczwj) View more	-	12 Jul 2019
				Anaferon for Children (Placebo)	objkmfexbd(pxqttuazwu) = bkybbyutsa uzeauhdfhs (zwjkwacwoc, ggpavrkdih - ndqshvpser) View more